Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$325.28 USD

325.28
1,270,338

+3.37 (1.05%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $325.29 +0.01 (0.00%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

by Zacks Equity Research

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

Kinjel Shah headshot

Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

by Kinjel Shah

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.

Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer

by Zacks Equity Research

Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.

Ekta Bagri headshot

3 Biotech Stocks Poised to Gain in the Second Half of 2021

by Ekta Bagri

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

LabCorp (LH) Expands Testing Portfolio With the Launch of CDx

by Zacks Equity Research

LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.

Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

by Zacks Equity Research

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group

Mark Vickery headshot

Top Analyst Reports for Alphabet, Visa & Eli Lilly

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and Eli Lilly (LLY).

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

by Zacks Equity Research

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

by Zacks Equity Research

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DEF

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Neena Mishra headshot

Should You Buy Biotech ETFs Now?

by Neena Mishra

Biotech stocks are rallying this month; can the trend continue?

Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

by Zacks Equity Research

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Kinjel Shah headshot

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

by Kinjel Shah

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study

by Zacks Equity Research

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

by Zacks Equity Research

QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

by Zacks Equity Research

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

by Zacks Equity Research

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

by Zacks Equity Research

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

Why Is Amgen (AMGN) Up 0.8% Since Last Earnings Report?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.